Exosomes, a subset of extracellular vesicles (EVs) ranging from 30–150 nm, have emerged as active participants in immune system regulation. Beyond serving as passive carriers of molecular cargo, these vesicles function as dynamic modulators, capable of influencing immune activation, tolerance, and homeostasis depending on the physiological and pathological context.
Various immune cells—dendritic cells, T and B lymphocytes, macrophages, and NK cells—secrete exosomes with specific molecular signatures that determine their immunomodulatory function:
Selective activation of CD8⁺ T lymphocytes. Through exosomes derived from dendritic cells presenting antigens and co-stimulatory molecules in a hierarchical manner, enhancing clonal expansion of effector cells and the generation of immune memory.
Tumor-mediated immunosuppression. Exosomes carrying PD-L1, FasL, TGF-β, IL-10, and regulatory microRNAs (miR-21, miR-155, miR-146a) inhibit NK and cytotoxic T cells, promoting peripheral tolerance and remodeling of the tumor microenvironment.
These mechanisms highlight the functional plasticity of exosomes, capable of acting both locally and systemically, precisely and coordinately modulating immunity.
Recent studies have shown that tumor-derived or mesenchymal stem cell-derived exosomes can:
Induce Treg expansion by transporting immunosuppressive molecules and specific miRNAs that regulate NF-κB and STAT3 signaling pathways.
Reprogram dendritic cells and macrophages towards tolerogenic phenotypes, reducing the expression of co-stimulatory molecules (CD80/CD86) and the production of pro-inflammatory cytokines.
Modulate the immunological synapse by interfering with TCR-MHC complex formation and limiting T lymphocyte activation.
These findings demonstrate that exosomes are active mechanisms of immune evasion and fine regulation, with direct implications in oncology, autoimmunity, and transplantation.
Understanding these mechanisms is paving the way for the development of next-generation therapeutic strategies:
Dendritic cell-derived exosomes loaded with tumor antigens capable of inducing highly specific CD8⁺ responses in preclinical cancer models.
Exosomes engineered to inhibit PD-L1 or deliver immunostimulants, enhancing T lymphocyte activation in immunosuppressive microenvironments.
Delivery vehicles for bioactive molecules via synthetic or hybrid exosomes, optimizing bioavailability and reducing systemic toxicity.
These strategies position exosomes as biocompatible, precise, and modulable therapeutic platforms, with potential to integrate personalized immunotherapy and precision medicine.
The development of high-purity isolation techniques, multi-parametric characterization, and advanced functional analysis will deepen our understanding. It will specifically enhance knowledge of the immunomodulatory mechanisms of exosomes. These approaches will also enable their use as clinical tools for designing therapies and immunological biomarkers. The combination of EV molecular profiling, genetic editing, and high-performance bioinformatics opens the door to highly specific therapeutic interventions. These interventions can be tailored to the complexity of the individual immune system.